Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide.
Aliment Pharmacol Ther
; 22(11-12): 1115-9, 2005 Dec.
Article
em En
| MEDLINE
| ID: mdl-16305725
ABSTRACT
BACKGROUND:
Budesonide (Entocort) is effective for the treatment of collagenous colitis.AIM:
To assess the long-term outcome of patients after induction of clinical remission by budesonide treatment.METHODS:
Fifty-one patients with chronic diarrhoea and histologically proven collagenous colitis were enrolled in randomized, placebo-controlled crossover trial using budesonide 9 mg daily for 6 weeks. Patients in clinical remission after either initial or crossover budesonide treatment were followed using standardized questionnaires. Clinical relapse was defined as five or more loose stools/day for at least 4 consecutive days.RESULTS:
A total of 33 patients achieved clinical remission (85% per-protocol). During a median follow-up of 16 months, clinical relapse occurred in 20 patients (61%), after a median time of 2 weeks (range 1-104, mean 10 weeks). Patient age <60 years was identified as a significant risk factor for clinical relapse (OR = 7.4, P = 0.048). Budesonide was used for treatment of clinical relapse in 80% of patients achieving clinical response in all of them.CONCLUSIONS:
Budesonide is effective in the treatment of collagenous colitis. Clinical relapses may occur in a considerable number of patients, particularly in those <60 years. Treatment of clinical relapse with budesonide appears to be an effective option.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Budesonida
/
Colite Colagenosa
/
Anti-Inflamatórios
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article